TOP TEN perturbations for NM_000134 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000134
Selected probe(set): 207475_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000134 (207475_at) across 5392 perturbations tested by GENEVESTIGATOR:

colorectal cancer study 33 (carcinoma; colonic mucosa) / normal colon mucosa sample

Relative Expression (log2-ratio):-2.0594864
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colon mucosa sample
Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

colorectal adenoma study 7 (colonic mucosa) / normal colon mucosa sample

Relative Expression (log2-ratio):-1.8290682
Number of Samples:5 / 5
Experimental colorectal adenoma study 7 (colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control normal colon mucosa sample
Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

Crohn's disease study 3 (baseline; non-responder; ileum) / normal ileum mucosa tissue

Relative Expression (log2-ratio):-1.7064133
Number of Samples:10 / 6
Experimental Crohn's disease study 3 (baseline; non-responder; ileum)
Ileal mucosal biopsies derived from Crohn's disease patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal ileum mucosa tissue
Ileal mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

colorectal cancer study 33 (carcinoma; colonic crypt) / normal colonic crypt epithelial cell sample

Relative Expression (log2-ratio):-1.5692339
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colonic crypt epithelial cell sample
Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

colorectal cancer study 33 (carcinoma; colonic mucosa) / adjacent colon mucosa sample

Relative Expression (log2-ratio):-1.4286814
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colon mucosa sample
Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

colorectal adenoma study 7 (colonic crypt) / normal colonic crypt epithelial cell sample

Relative Expression (log2-ratio):-1.419014
Number of Samples:5 / 5
Experimental colorectal adenoma study 7 (colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control normal colonic crypt epithelial cell sample
Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

colorectal cancer study 33 (carcinoma; colonic crypt) / adjacent colonic crypt epithelial cell sample

Relative Expression (log2-ratio):-1.236124
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colonic crypt epithelial cell sample
Adjacent colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

Crohn's disease study 10 / normal colon tissue

Relative Expression (log2-ratio):-1.2113819
Number of Samples:4 / 3
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control normal colon tissue
Colon biopsies derived from healthy controls.

colorectal cancer study 33 (carcinoma; cecum) / normal cecum tissue

Relative Expression (log2-ratio):-1.2023926
Number of Samples:4 / 2
Experimental colorectal cancer study 33 (carcinoma; cecum)
Primary tumor samples derived from the cecum of patients with carcinoma.
Control normal cecum tissue
Normal cecal tissue samples.

colorectal adenoma study 7 (colonic mucosa) / adjacent colon mucosa sample

Relative Expression (log2-ratio):-1.1982632
Number of Samples:5 / 5
Experimental colorectal adenoma study 7 (colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control adjacent colon mucosa sample
Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer.